Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Shares Tumble 15.5 Percent on Q3 Revenue Decline, Preclinical Divestiture

NEW YORK (GenomeWeb News) — Shares in Gene Logic were down 15.47 percent, or $.30, at $1.64 in midday trading after the company this morning said third-quarter revenue slid 39 percent, and that it plans to sell its preclinical services division.
 
After stating in September that the preclinical services segment would not be put on the block, today Gene Logic said it has hired an investment firm to help it divest the unit, and is currently in discussions for the sale.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.